Why the study?
YAP is related to cardiovascular disease pathology, but its role in cardiac injury of diabetic cardiomyopathy is still unclear.
Does YAP knockdown reduce myocardial fibrosis and improve cardiac function in a rat model of diabetic cardiomyopathy?
Population
Diabetic cardiomyopathy rat model and primary rat cardiac fibroblasts
Comparison
Control vs DCM vs LV-SC-shRNA vs LV-YAP-shRNA
Design
Preclinical animal and in vitro laboratory study
Key result
YAP knockdown reduced myocardial fibrosis and improved cardiac function in a rat model of diabetic cardiomyopathy by decreasing the expression of CTGF and fibronectin.
Authors
Loading...
Does not change clinical practice in diabetic cardiomyopathy; leaves open YAP as a therapeutic target pending human studies.
Does YAP knockdown reduce myocardial fibrosis and improve cardiac function in a rat model of diabetic cardiomyopathy?
YAP knockdown reduces myocardial fibrosis and improves cardiac function in a rat model of diabetic cardiomyopathy, identifying YAP as a potential therapeutic target.
Hu et al. (2021) studied Diabetic cardiomyopathy. YAP-shRNA vs. SC-shRNA and untreated DCM control was evaluated on Myocardial fibrosis, cardiac function, and expression of CTGF and fibronectin. YAP knockdown reduced myocardial fibrosis and improved cardiac function in a rat model of diabetic cardiomyopathy by decreasing the expression of CTGF and fibronectin.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: